Results 161 to 170 of about 559,417 (315)
Evidence-based medicine: challenging the orthodoxy [PDF]
David G. Grahame‐Smith
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review. [PDF]
Untaaveesup S+7 more
europepmc +1 more source
Evidence-based medicine and the practicing clinician
Finlay A. McAlister+3 more
openalex +2 more sources
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma. [PDF]
Shinozaki T+33 more
europepmc +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
Metabolic Reprogramming of Urothelial Carcinoma-A Theragnostic Target for Betulinic Acid. [PDF]
Ganguly A+7 more
europepmc +1 more source
Clinical observation on treatment of postcardiotomic complications with Chinese herbal medicine based on syndrome differentiation in 58 patients with angiocardiopathy [PDF]
Lihong Ma, Zeng-mian Jiao, Ruihua Zhang
openalex +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source